Acrobiosystems Co Bruttokate

Mitä Acrobiosystems Co tekee? Acrobiosystems Co Ltd is a biotechnology company based in Beijing, China, operating within the Health Care sector. The company specializes in the development of biomedicine and bio-protein technology, focusing on recombinant proteins, detection services, and related products such as kits, antibodies, fillers, and culture media. With 597 full-time employees, Acrobiosystems provides services and products primarily for research and development (R&D) and production processes in the pharmaceutical and biotechnology industries. Its offerings support early drug discovery, verification, drug screening, optimization, diagnostic reagent development, and preclinical and clinical trials for various diseases, including tumors, autoimmune disorders, cardiovascular conditions, and infectious diseases. The company completed its initial public offering (IPO) on October 18, 2021, and is listed under the ticker symbol 301080.SZ with ISIN CNE100004S13. Acrobiosystems operates from its headquarters in Beijing, leveraging its technological expertise to contribute to advancements in drug development and diagnostic solutions. The company's website is https://www.acrobiosystems.cn/. Acrobiosystems Co on yksi Eurpooliin suosituimmista yhtiöistä.